INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Gravier Pierre sold PTCT

CHIEF FINANCIAL OFFICER · PTC THERAPEUTICS, INC. · Common Stock

Side
SELL
Value
$165K
Shares
2,139
Price
$76.95
Executed
Jan 6, 2026
Disclosed
Jan 8, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 6 executedJan 8, 2026 disclosed

PTCT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
18/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+4 / 25

    $165K reported value · 2.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PTCT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    4
    KB
    Klein Matthew B.Director, CHIEF EXECUTIVE OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$202K
    2,850 sh
    		Apr 21, 2026Apr 23, 2026
    traded Apr 21, 2026
    		+2dSEC FORM 4

    Evidence

    8
    GS
    Golden Lee ScottEVP & CHIEF MEDICAL OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$56K
    829 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    0
    CC
    Chutter Jessica CarolineDirector
    PTCTPTC THERAPEUTICS, INC.
    Grant or award · 10b5-1 plan
    		A—
    4,000 sh
    		Mar 24, 2026Mar 26, 2026
    traded Mar 24, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CC
    Chutter Jessica CarolineDirector
    PTCTPTC THERAPEUTICS, INC.
    Grant or award · 10b5-1 plan
    		A—
    2,896 sh
    		Mar 24, 2026Mar 26, 2026
    traded Mar 24, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CC
    Chutter Jessica CarolineDirector
    PTCTPTC THERAPEUTICS, INC.
    Grant or award · 10b5-1 plan
    		A—
    3,475 sh
    		Mar 24, 2026Mar 26, 2026
    traded Mar 24, 2026
    		+2dSEC FORM 4

    Evidence

    11
    CC
    Chutter Jessica CarolineDirector
    PTCTPTC THERAPEUTICS, INC.
    Grant or award · 10b5-1 plan
    		A—
    3,333 sh
    		Mar 24, 2026Mar 26, 2026
    traded Mar 24, 2026
    		+2dSEC FORM 4

    Evidence

    4
    GP
    Gravier PierreCHIEF FINANCIAL OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$208K
    2,992 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    18
    UM
    Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$79K
    1,034 sh
    		Jan 8, 2026Jan 12, 2026
    traded Jan 8, 2026
    		+4dSEC FORM 4

    Evidence

    14
    KB
    Klein Matthew B.Director, CHIEF EXECUTIVE OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$192K
    2,514 sh
    		Jan 8, 2026Jan 12, 2026
    traded Jan 8, 2026
    		+4dSEC FORM 4

    Evidence

    14
    KB
    Klein Matthew B.Director, CHIEF EXECUTIVE OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$234K
    3,016 sh
    		Jan 7, 2026Jan 8, 2026
    traded Jan 7, 2026
    		+1dSEC FORM 4

    Evidence

    17
    KB
    Klein Matthew B.Director, CHIEF EXECUTIVE OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$396K
    5,149 sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GP
    Gravier PierreCHIEF FINANCIAL OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Grant or award
    		A—
    50.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    17
    GP
    Gravier PierreCHIEF FINANCIAL OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Grant or award
    		A—
    20.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    27
    KB
    Klein Matthew B.Director, CHIEF EXECUTIVE OFFICER
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$620K
    8,089 sh
    		Dec 30, 2025Jan 2, 2026
    traded Dec 30, 2025
    		+3dSEC FORM 4

    Evidence

    0
    RE
    Reeve EmmaDirector
    PTCTPTC THERAPEUTICS, INC.
    Option exercise · 10b5-1 plan
    		M—
    10.0K sh
    		Nov 21, 2025Nov 25, 2025
    traded Nov 21, 2025
    		+4dSEC FORM 4

    Evidence

    19
    RE
    Reeve EmmaDirector
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$795K
    10.0K sh
    		Nov 21, 2025Nov 25, 2025
    traded Nov 21, 2025
    		+4dSEC FORM 4

    Evidence

    13
    RE
    Reeve EmmaDirector
    PTCTPTC THERAPEUTICS, INC.
    Option exercise · 10b5-1 plan
    		M$512K
    10.0K sh
    		Nov 21, 2025Nov 25, 2025
    traded Nov 21, 2025
    		+4dSEC FORM 4

    Evidence

    16
    OS
    Okey StephanieDirector
    PTCTPTC THERAPEUTICS, INC.
    Gift
    		G—
    867 sh
    		Nov 20, 2025Nov 21, 2025
    traded Nov 20, 2025
    		+1dSEC FORM 4

    Evidence

    0
    RE
    Reeve EmmaDirector
    PTCTPTC THERAPEUTICS, INC.
    Option exercise · 10b5-1 plan
    		M—
    7,333 sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    23
    RE
    Reeve EmmaDirector
    PTCTPTC THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$546K
    7,333 sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001984065-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 6, 2026
    Published
    Jan 8, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Gravier Pierre
    Role
    CHIEF FINANCIAL OFFICER
    Transaction
    Open-market saleAs filed: “S”
    Asset
    PTC THERAPEUTICS, INC.
    Ticker
    PTCT
    Shares
    2,139
    Price per share
    $76.95
    Value
    $164,596
    Execution date (reported)
    Jan 6, 2026
    Owned after transaction
    90.3K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 2,139
    • Price: $76.95

    = $164,596

    What this establishes

    Gravier Pierre filed this Form 4 reporting a open-market sale of PTCT on Jan 6, 2026. It became public on Jan 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CHIEF FINANCIAL OFFICER
    Gravier Pierrecik:0001984065
    Issuer
    PTC THERAPEUTICS, INC.cik:0001070081

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.